Commercial-stage biotechnology company Krystal Biotech Inc (NASDAQ:KRYS) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Fast Track designation for inhaled KB707 to treat solid tumours with pulmonary metastases that are relapsed or refractory to standard therapy.
KB707, a modified HSV-1 vector designed to deliver interleukin-12 and interleukin-2 genes to the tumour microenvironment, aims to promote immune-mediated tumour clearance.
In January 2024 the FDA cleared the Investigational New Drug (IND) application for Phase 1 clinical trial KYANITE-1, set to commence in the first half of 2024, targeting patients with locally advanced or metastatic solid tumours of the lung.
This is the second Fast Track for KB707, following the FDA's previous approval for intratumoral KB707 in melanoma treatment.
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas